Team

Prior to assuming his current role at Interius, Phil was the founding CSO, President, and Interim CEO of Limelight Bio from 2016 – 2020. For the three preceding decades, he led large research enterprises at two of the world’s premier academic pediatric hospitals while receiving multiple national honors including election to the American Pediatric Society and being named a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology.

Phil received undergraduate and medical degrees from the University of North Carolina and then completed pediatrics residency and infectious diseases fellowship training at Vanderbilt University and the National Institutes of Health. He is considered an international leader in viral vector technology and human gene transfer.

Before joining Interius, Dora served as Vice President of Business Development and Vice President of Operations of Carisma Therapeutics, where she was on the founding team. Prior to the launch of Carisma, Dora managed a portfolio of 60 startup companies at PCI Ventures at the University of Pennsylvania as Director of the UPstart Company Incubator, often acting as “entrepreneur-in-residence” for companies in the life sciences portfolio. She has held roles spanning pre-clinical, early clinical, management and board positions in young companies including NellOne Therapeutics, Cognizance Biomarkers (acquired), CytoVas, LignaMed, Linnaeus Therapeutics Inc., Quantitative Radiology Solutions and Ophidion, Inc.

Dora fell in love with early-stage companies while a member of the Health and Life Sciences team at Battelle Ventures, LP, an early-stage life science and technology venture capital fund. She serves as founding investment committee member of Nassau Street Ventures. Dora holds a PhD in Molecular Biology from Princeton University.

Tim joins Interius following a distinguished 14-year career with Merck Research Laboratories where he supported vaccine and oncolytic virus program development as a Senior Principal Scientist.  His experience includes leadership of both early and late-stage development teams responsible for all CMC deliverables needed for clinical programs.  Tim enjoys working closely with both scientists and process engineers on research and development teams to help overcome technical obstacles and enable team success. His background includes extensive experience working with regulatory agencies to advance novel live virus candidates.

Tim was awarded a Ph.D. from the Pennsylvania State University, College of Medicine for his research on human papillomaviruses.  He subsequently completed post-doctoral studies at Penn State developing chimeric papillomavirus vaccines.  Tim holds a B.S. in Biology/Secondary Education from Christian Heritage College and had a 15-year high school teaching career prior to his graduate studies.

Jessica has more than 20 years of experience in pharmaceutical development and over eight years of experience working in cell and gene therapies.

She started her career working for Ernst & Young consulting to hospital networks within New Zealand and in 2002 joined GlaxoSmithKline, where she worked across discovery and development functions in strategic and operational roles.  In 2012, Jessica joined the GSK Rare Diseases Team and worked cross-functionally to help deliver ground-breaking cell and gene therapy treatments for multiple immunodeficiency and leukodystrophies.  In 2016, she led the European launch of the first autologous ex-vivo gene therapy (Strimvelis) for children born with ADA Severe Combined Immunodeficiency (SCID) and through 2018 Jessica led the rare growth strategy plans for cell and gene therapy treatments worldwide for GSK. Jessica also brings small biotech gene therapy experience to Interius, having led the development of two programs towards IND submission at Limelight Bio.

Jessica received her MBA in healthcare and pharmaceuticals from Drexel University, Philadelphia and her undergraduate degree in Strategic Management and Industrial Psychology at the University of Waikato in New Zealand.

Jim leads analytical development at Interius, cutting across all scientific efforts at the company. Trained as a virologist, Jim has over 25 years of experience developing viral products for the prevention and treatment of disease. Jim comes to Interius from Altimmune, where he was Director of Scientific Affairs.

Previously, Jim led the cell and gene therapy standards development efforts at US Pharmacopeia. In previous roles at Advanced BioScience Laboratories and Foundation Fighting Blindness, he led translational science activities for the development of vaccines and biologics to prevent and treat infectious and retinal diseases.  Jim has also held positions responsible for performing viral clearance and adventitious agent testing at Viromed Biosafety as well as AAV vector development and characterization at Genovo/Targeted Genetics.

Jim received his Bachelor of Science degree in Microbiology from Cornell University, his Master of Science in Microbiology from Colorado State University, and his PhD in Biomedical Sciences at the Mount Sinai School of Medicine.

Bruce brings over 20 years of experience developing viral vector technologies with an emphasis in adeno-associated virus vectors. Prior to Interius he served as Senior Director, Technology Development at Kriya Therapeutics, where he was responsible for vector design and assay development.  Previously, Bruce held key scientific roles at Limelight Bio, where he led a team of scientists developing both AAV-mediated and non-viral therapeutics for genetic diseases, and with The Children’s Hospital of Philadelphia, where he was involved in the preclinical design and development of the first-in-human study that used a recombinant AAV vector to deliver a gene for a monoclonal antibody to block HIV infection.

Bruce received his Ph.D. in Molecular Genetics from The Ohio State University and completed his postdoctoral work at Nationwide Children’s Hospital in Columbus, Ohio. He received his undergraduate degree in Biology from Purdue University.

Jim brings to Interius over 12 years of experience in bioengineering, immunology, and material science to lead the Discovery research efforts in cell-based assays and preclinical animal models. Prior to joining Interius, Jim’s research focused on understanding the interplay between injectable materials and immunological responses where he implemented a variety of mouse models and utilized flow cytometry readouts and next-generation sequencing to identify cells and pathways of interest.

Jim received a B.S./M.S. degree in Biomedical Engineering from Drexel University and holds a Ph.D. in Bioengineering from the University of Maryland, College Park. Prior to joining Interius in July of 2020, Jim completed his postdoctoral research at Johns Hopkins University.

Scott is focused on planning new programs and deriving value from our company’s ongoing work through IP generation and capture.  Scott is a genetic engineer with over a decade of experience in the fields of genetics and gene therapy. Throughout his career he has integrated computer and biological sciences to design and implement creative gene therapy strategies. Prior to joining Interius he worked at Spirovant Sciences, and previously at Limelight Bio developing lentivirus and AAV platforms for the treatment of diseases with unmet needs.

Scott received his BA degree in Genetics from Rutgers University and his Ph.D. in Cellular and Molecular Biology, with a concentration in Gene Therapy, from the University of Pennsylvania.

Tricia leads human resources at Interius combining her passion for science and people. She started her career in the pharmaceutical industry as a Research Scientist. Following her time at the bench, she held various roles in R&D and Marketing prior to moving into Human Resources.

Tricia’s 20-year corporate experience spans large, midsize and small pharmaceutical companies including Merck, Otsuka, Valeant, Biovail, Celgene and has included working closely with both scientific and corporate divisions, delivering on projects spanning from recruitment to post-merger integrations, all with a keen ability to understand and connect people, processes and technology.

Tricia holds a BS degree in Microbiology from the Pennsylvania State University and a MPS degree in Industrial Labor Relations from Cornell University. She is a graduate of the Institute for Professional Coaches and is a Six-sigma green belt.

Babu is an experienced pharmaceutical scientist with more than 16 years of biotech and pharmaceutical development experience across multiple modalities including monoclonal antibodies, recombinant protein vaccines, live virus vaccines, and cell therapies. He is well recognized in the drug product development area with several publications and patent applications. Babu is passionate and excited to be involved in developing cell & gene therapies to address unmet medical needs and to improve accessibility for patients.

Prior to joining Interius, Babu was Director of Formulation and Drug Product Development at Allogene Therapeutics, playing critical roles in multiple allogeneic CAR T cell therapy programs’ advancement from bench to clinic, tech transfer for drug product manufacturing, IND filings and pivotal process development, and process characterization for the lead program.  Previously, Babu spent 10 years within the Vaccine Drug Product Development group at Merck & Co. leading formulation and drug product process development for multiple novel vaccine candidates including liquid, lyophilized and adjuvanted formulations. Babu led development teams, tech transfer, clinical drug product manufacturing campaigns for multiple products and modalities spanning early to late-stage development. Prior to Merck, he worked on novel formulations and delivery systems for vaccines and biologics at DelSite Biotechnologies.

Babu received his bachelor’s degree in Pharmacy from Andhra University, India and PhD in Pharmaceutical Sciences from North Dakota State University, Fargo, ND. He is a Registered Pharmacist in the states of Texas and Pennsylvania.

Sianny joins Interius as the Senior Director of Process Development. Sianny brings to Interius a wealth of experience in both process development and manufacturing of live viruses, VLPs, and recombinant proteins gained during a well-respected 22-year career at Merck.

In addition to her strong technical expertise in both upstream and downstream process development, Sianny possesses excellent leadership abilities demonstrated by her success in leading teams supporting early and late phase clinical programs, and commercial manufacturing.

Sianny has a Bachelor of Science in Chemical Engineering from the University of Wisconsin-Madison.

Lovisha joins Interius as Finance Controller having most recently served as Controller and Associate Director at Century Therapeutics, where she was intimately involved with taking the company to a successful IPO in June of 2021. Previously, she had positions of increasing responsibility in finance at Cardiokine, Complexa, Tarsa Therapeutics, and Flowmetric, where she was Global Corporate Controller. Lovisha brings to Interius more than 10 years of experience in the Accounting/Finance and Human Resource environments exclusively in the pharmaceutical and biotechnology field, specializing in accounting process and controls, cash flow forecasting, process improvement, operations and marketing, budgetary planning, metrics analysis, reporting and stakeholder engagement.

Lovisha holds a master’s degree in Accounting and Financial Management from DeVry University’s Keller Graduate School of Management and is a Pennsylvania Certified Public Accountant.

Matt is an expert in high throughput analytical development, assay automation, liquid handling, and data analysis, supporting early discovery screening and analytical efforts throughout Interius.

Before Interius, Matt had a 15-year career at Merck Research Laboratories within Vaccine Analytical R&D.  There, he worked as an automation scientist and analytical project lead supporting various live virus, polysaccharide conjugate, and recombinant protein vaccines, in addition to oncolytic virus programs.  During this time in VAR&D, Matt focused on the development, automation, and deployment of various high throughput biochemical, immunological and cell-based assays.

Matt received his B.S. in Bioengineering, and an accompanying Minor in Mathematics, from the Pennsylvania State University.  His professional experience includes leadership in assay development, laboratory automation, Quality by Design (QbD), Design of Experiments (DOE), applied statistics and CMC analytical program leadership.

During his more than 35 year career in biotechnology, Bruce Peacock has held numerous senior leadership positions, including President and Chief Executive Officer of Adolor Corporation, Alba Therapeutics and Orthovita, Inc., and Chief Financial Officer (CFO) and Business Officer of Ophthotech. For over 10 years, he served as Venture Partner with SV Life Sciences Health Investors. Previously, he was Executive Vice President and Chief Operating Officer of Cephalon Inc. and prior to this, he was CFO at Centocor, Inc. He is a member of the Board of Directors of Ocular Therapeutics, PanOptica and Windtree Therapeutics. Bruce is committed to nurturing young biotechnology companies in Philadelphia: he was instrumental in the growth of Carisma Therapeutics, focused on novel cell therapies for cancer, and of Aro BioTherapeutics, developing targeted genetic medicines. Bruce holds a BA in Business Administration from Villanova University.

Saar is an assistant professor of medicine at the University of Pennsylvania where he specializes in the treatment of patients with leukemia and in bone marrow transplantation. He has led clinical trials of chimeric antigen receptor (CAR) T cell trials for chronic and acute leukemias. His research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering. Saar is a foremost innovator in the cell and gene therapy space as evidenced by his being one of the most prolific patent inventors in the field globally as well as his creation of two biotherapeutics companies: Carisma Therapeutics, developing macrophage-based cellular therapeutics, and Interius BioTherapeutics, focused on specific in vivo delivery of gene therapies.

Saar obtained his medical degree and PhD in immunology from the University of Melbourne in Australia, and completed a post-doctoral fellowship in cellular therapy at Stanford University.

Richard retired from Merck as a Vice President at the end of 2018 where he had responsibility and leadership for all Vaccine Bioprocess Research and Development, and he held a similar role for Merck Biologics Bioprocess, R&D.  Prior to Merck, Richard was Vice President of Process Sciences and Manufacturing at Genovo and Targeted Genetics.

He received his B.A. in Biology from the University of Maryland Baltimore County and his Ph.D. from The Rockefeller University. After a post-doc at the UCSF and Vanderbilt University, Richard was a faculty member at Jefferson University, University of Minnesota, and Mt. Sinai School of Medicine. After leaving Merck, he formed RWP BioConsulting, LLC to bring his expertise and experience to serve the life science industries. He currently sits on the Editorial Board for the publication Human Gene Therapy.

Mike earned his Ph.D. in 1998 from the University of North Carolina in Dr. Jeffrey Frelinger’s lab working on human T cell responses to HIV. He continued this work during his postdoctoral fellowship with Dr. Rick Koup at the University of Texas Southwestern Medical Center and then at the NIH Vaccine Research Center.

Mike is a Professor in the Department of Microbiology at the University of Pennsylvania School of Medicine, where in 2005 he started his NIH-funded lab and where he continues to research the immune response to HIV and other viral infections in humans, most recently working on COVID-19. Mike maintains active collaborations in Latin America, Europe, and Africa, where he is involved in both immunology research studies and training of new investigators.

Jim Ackland is the Managing Director of Global BioSolutions and has over 45 years’ experience in the manufacture, quality control, development and international regulatory requirements for pharmaceutical products. He has been involved in more than 20 vaccine development projects as the lead regulatory advisor and preclinical safety expert and has filed dozens of successful clinical trial applications in the US, Europe and Australia. Jim spent 26 years at CSL Limited in Melbourne where he held various leadership positions in vaccine manufacture, quality assurance and research and development, including Head of Regulatory Affairs for Vaccine Products. Following this, he became Vice President for the Biologics Consulting Group, an internationally recognized pharmaceutical regulatory consulting company, based in California.  Jim is currently CEO of Global BioSolutions, an Australian company which provides regulatory and product development advice and assistance to biotech companies.

Erika De Boever has over 20 years’ experience in clinical development and project leadership in the pharmaceutical and biotech industry with extensive expertise in AAV and LVV gene therapies for rare and common diseases.

Ms. De Boever has hands-on clinical development, translational medicine and program strategy consulting services for small and large molecules across all stages of development, from pre-IND/CTA to Phase IV. She currently serves on the Scientific Advisory Board for the Center for Dental, Oral and Craniofacial Tissue and Organ Regeneration (C-DOCTOR) and the Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center.

During her tenure at GSK, Ms. De Boever was a lead clinical development scientist in development and approval of Strimvelis, the first pediatric gene therapy for the treatment of ADA-SCID, and in the development of Libmeldy for the treatment of metachromatic leukodystrophy (MLD).

Ms. De Boever has a DDS from the University of Ghent (Belgium) and an MPH and PhD from the University of Michigan.

Emberly Dumayas is a clinical operations professional with 20 years of progressive leadership experience as a people leader, Clinical Study Manager, Clinical Team Lead, Clinical Research Associate, and coordinator for pharmaceutical, medical device, and IVD trials/studies. She takes complex clinical trials through all phases: protocol strategy, design, budgeting, negotiation, trial management, and close-out for Phase I/II-IV, Class II/Class III, and 510(k) research.

Ms. Dumayas has built her knowledge in clinical operations through complex clinical trials at all development phases: protocol strategy, design, budgeting, negotiation, trial management, and close-out for Phase I/II-IV, Class II/Class III PMA, and 510(k) research. She took strategic leadership roles at Sio Gene Therapies as a Senior Director and as Head of Clinical Operations at Freeline Therapeutics to drive development of novel gene therapies for patients with lysosomal storage disorders such as Tay-Sachs, Sandhoff, Fabry, and Gaucher Disease. Prior to these roles she held operational roles at Sanofi, IQVIA, Grifols and Exact Sciences where she supported development of biologics, medical device, and small molecule products through clinical trials.

Ms. Dumayas received her undergraduate degree in English and Biology from Ripon College and has most recently attended courses at the University of North Carolina – Chapel Hill, Kenan-Flagler Business School to attain a Certificate in Strategic Leadership.

Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Associate Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology.

Dr. Abramson’s clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, as well as Hodgkin lymphoma, and chronic lymphoid leukemias. His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and a Fellow of the American College of Physicians. Dr. Abramson is the author of numerous papers and book chapters on lymphoma, and lectures widely.

Michael Dickinson is the Lead of the Aggressive Lymphoma disease group within Clinical Hematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He specializes as a principal investigator in phase I/II clinical trials of new anticancer drugs with a current focus on Aggressive Lymphomas and novel immunotherapies, and with experience across a breadth of hematological malignancies. His investigator-initiated studies have focused on the role of epigenetic modifiers in hematological malignancies, eltrombopag as a supportive care agent in MDS/AML, and new CART therapies. Dr. Dickinson’s clinical research includes industry and investigator-led trials in aggressive lymphoma, phase 1 studies, and CART trials. Dr. Dickinson is a leading investigator in pivotal clinical trials of CART for Follicular Lymphoma (ELARA, tisagenlecleucel) and DLBCL (Zuma7, Zuma12 and BELINDA). He is an investigator on phase 1 studies of CART and CAR-NK cell trials and is the senior author in the CD20/CD3 bispecific glofitamab phase 1 and pivotal trial and combination program. He has over 100 publications including in New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood.

Dr. Dickinson’s greatest professional satisfaction comes from making individual patients feel better. He believes in research-led clinical care, and placing a patient’s individual circumstances to the fore when developing a treatment plan that is not only evidence-based, but which is also right for them.

Dr. David Maloney develops new treatments for patients with lymphomas, leukemias and myeloma as well as other cancers. He is widely recognized as an expert in treating people with these cancers. The focus of his laboratory and clinical research is immunotherapies, which are treatments that can enhance anti-cancer immune responses. One strategy uses immune cell products known as antibodies. Dr. Maloney was instrumental in the development and testing of rituximab, the first antibody-based cancer drug on the market. This drug has transformed the treatment of certain leukemias and lymphomas. Dr. Maloney also is developing genetically engineered immune cell therapies, which are called CAR T-cell therapies, for various cancers. He is the first medical director for cellular immunotherapy at Fred Hutch and the Bezos Family Immunotherapy Clinic at Fred Hutchinson Cancer Center, where these strategies are being used to treat patients.

The focus of Dr. Nastoupil’s research has been on examining disparities in lymphoma survival to identify opportunities to design and implement rational clinical trials aimed at improving outcomes for high-risk patients. She has completed analyses using large databases in follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) identifying characteristics that predict for inferior outcomes. Her early efforts in this arena identified disparities in the use of potentially-curative, chemo-immunotherapy in the treatment of DLBCL patients. This study demonstrated that race and insurance status were associated with significant differences in the administration of chemo-immunotherapy among US patients with DLBCL. This sparked Dr. Nastoupil’s interest in pursuing divergent approaches for addressing these disparities. She has conducted translational work, molecularly profiling tumors of patients with DLBCL to identify biologic variances that may explain the racial differences in DLBCL at presentation and differences in survival. Dr. Nastoupil is the director of the Lymphoma Outcomes Database at MDACC with prospective data collection linked to a tissue repository and continue exploration of predictors of lymphomagenesis and outcomes. This work informs clinical trial designs in her work. She is also experienced in conducting clinical trials in patients with lymphoma and has served as Principal Investigator in phase I, II, and III clinical trials including several investigator-initiated studies. Dr. Nastoupil has expertise and demonstrated proficiency in regards to patient care, safety, and coordination of numerous research and administrative staff.

Marion Subklewe is Head of the Laboratory for Translational Cancer Immunotherapy at the Gene Center, Munich and the Head of Flow Cytometry for the Laboratory of Leukemia Diagnostics at the Ludwig Maximillian University of Munich, Germany (LMU Munich).  Dr. Subklewe is also a Professor of Internal Medicine, with a focus on Cellular Immunotherapy, at LMU Munich.

Professor Subklewe completed her residency at University Hospital Tübingen and her postdoctoral fellowship at Rockefeller University in New York as a DFG-Scholar and Cure for Lymphoma Fellow.

Dr. Subklewe is active in clinical research and has been Principal Investigator in three I-IT trials in AML and ALL.  In recognition of her work, Professor Subklewe has received numerous honors and awards including the EHA Educational Presentation and ASH Abstract Achievement Awards.

Lonnie serves as our Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a Boston based oncology-focused biopharmaceutical company) and served as CEO until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder is Executive Chair of Zenas BioPharma, serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and also the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.

Prior to assuming his current roles at Interius, Phil was the founding CSO, President, and Interim CEO of Limelight Bio from 2016 – 2020. For the three preceding decades, he led large research enterprises at two of the world’s premier academic pediatric hospitals while receiving multiple national honors including election to the American Pediatric Society and being named a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology. Phil received undergraduate and medical degrees from the University of North Carolina and then completed pediatrics residency and infectious diseases fellowship training at Vanderbilt University and the National Institutes of Health. He is considered an international leader in viral vector technology and human gene transfer.

Bihua Chen is the Founder of Cormorant Asset Management, LP, an investment firm focused on innovative biotech, medtech and life science companies with over $3 billion in assets under management. Prior to founding Cormorant, Ms. Chen managed an account focused on the health care sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. Ms. Chen holds a BS in genetics and genetic engineering from Fudan University, an MS in molecular biology from the Graduate School of Biomedical Science at Cornell Medical College and an MBA from the Wharton School of Business.

Tomas is currently managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak served as a managing director at RA Capital Management LLC, based in Boston. Tomas also serves on the board of directors of Zenas BioPharma , Dianthus Therapeutics, and Viridian Therapeutics. He received his BA in Neuroscience and Economics from Amherst College.